Adam P. Siegel
Distinguished in Chronic T-Cell Leukemia (CTCL)

Dr. Adam P. Siegel

Hematology | Oncology
36500 Aurora Dr, 
Summit, WI 
On Staff At
Offers Telehealth
Distinguished in Chronic T-Cell Leukemia (CTCL)
36500 Aurora Dr, 
Summit, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Adam Siegel is a Hematologist and an Oncologist in Summit, Wisconsin. Dr. Siegel is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Adult T-Cell Leukemia, Chronic T-Cell Leukemia (CTCL), Familial Prostate Cancer, and Angiosarcoma.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
University of California - San Francisco, Internal Medicine
Specialties
Hematology
Oncology
Licenses
Internal Medicine in WI
Board Certifications
American Board Of Internal Medicine, Hematology
Fellowships
University of California - San Francisco, Hematology/Oncology
Hospital Affiliations
Aurora St Lukes Medical Center
West Allis Memorial Hospital
Aurora Medical Ctr Washington County
Aurora Medical Center - Summit
Waukesha Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Common Ground Healthcare
  • OTHER COMMERCIAL
Common Ground Healthcare Cooperative
  • EPO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Icare Independent Care Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Network Health
  • HMO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Quartz
  • HMO
  • POS
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 22 Less Insurance Carriers -

Locations

Vince Lombardi Cancer Clinic
36500 Aurora Dr, Summit, WI 53066

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: October 10, 2025
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2024
Intervention Type: Other, Biological, Drug
Study Drugs: Panitumumab, Regorafenib, Trifluridine, Tipiracil
Study Phase: Phase 2
Phase II Single Agent Study of Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide
Phase II Single Agent Study of Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide
Enrollment Status: Terminated
Publish Date: June 26, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

5 Total Publications

Using prediction markets to predict the outcomes in the Defense Advanced Research Projects Agency's next-generation social science programme.
Using prediction markets to predict the outcomes in the Defense Advanced Research Projects Agency's next-generation social science programme.
Journal: Royal Society open science
Published: August 08, 2018
Similar Doctors
Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Mete Korkmaz
Oncology | Hematology
Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Mete Korkmaz
Oncology | Hematology

Osf Multi-Specialty Group

5666 E State St, 
Rockford, IL 
 (61.5 miles away)
815-921-8929
Languages Spoken:
English
See accepted insurances

Mete Korkmaz is an Oncologist and a Hematologist in Rockford, Illinois. Dr. Korkmaz is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Paget Disease of the Breast, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Angiosarcoma, and Bone Marrow Aspiration.

Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Christopher R. Hake
Hematology Oncology | Oncology | Hematology
Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Christopher R. Hake
Hematology Oncology | Oncology | Hematology

Prohealth Medical Group Inc

240 Maple Ave, 
Mukwonago, WI 
 (16.9 miles away)
262-928-1900
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Christopher Hake is a Hematologist Oncology specialist and an Oncologist in Mukwonago, Wisconsin. Dr. Hake is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, and Breast Cancer. Dr. Hake is currently accepting new patients.

Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Michael E. Keefe
Hematology Oncology | Hematology | Oncology
Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Michael E. Keefe
Hematology Oncology | Hematology | Oncology

Columbia St Marys Hospital Milwaukee Inc

2350 N Lake Dr, 
Milwaukee, WI 
 (29.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Keefe is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. Keefe is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Thrombocytopenia, Unicentric Castleman Disease (UCD), Multicentric Castleman Disease (MCD), and Castleman Disease. Dr. Keefe is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Siegel's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 40 Advanced Conditions
    View All 99 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile